Prostate Cancer

Overall, 59% of patients achieved at least a 50% decline in PSA level.

The company plans to submit a Biologics License Application to the FDA at the end of 2026.

However, the data did not show any benefit of a docetaxel doublet vs an ARPI doublet.

The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.

The AI tool outperformed MRI in assessing for SVI.

Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.

The phase 3 study design will now be submitted for final review by the agency.

According to Adam B. Weiner, MD, a urologist at Cedars-Sinai Medical Center, men should begin prostate cancer screening around ages 50 to 55.

The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.

Research reveals that lower PSA levels in metastatic hormone-sensitive prostate cancer significantly delay disease progression and improve patient outcomes.

Research highlights the significant benefits of achieving ultra-low PSA levels in metastatic hormone-sensitive prostate cancer, delaying disease progression effectively.

Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.

“I think it does give us confidence that clinical trials can predict how these drugs will work in the real world," says Stephen J. Freedland, MD.

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

Recent data suggest that obesity may be a risk factor for increased pain on transperineal biopsy.

Use of focal therapy was shown to prolong the duration of active surveillance.

The study was published in JCO Oncology Practice.

A panelist discusses how ARANOTE contributes to the evidence for treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), comparing it with other trials like ARCHES, TITAN, and LATITUDE while highlighting the nuanced differences in adverse effect profiles and tolerability among these agents.

A panelist discusses how the ARANOTE phase 3 trial investigated darolutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, providing an overview of the study design and topline results.

The miR Sentinel Prostate Cancer Test is a standalone liquid biopsy urine test.

Investigators found that benefits of treatments that are observed in trials also appear in the real world.

The trial has enrolled 201 patients with localized prostate cancer to date.

Initial study results may be available as soon as the first half of 2026.

"To me, the key take-home is that the benefits that we see in clinical trials, we actually can replicate in the real world," says Stephen J. Freedland, MD.

The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”

The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.

More than 80% of patients in both groups had a full recovery of testosterone.

Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.

Clarius Mobile Health said it will be demonstrating the application at the AUA Annual Meeting in Las Vegas, Nevada.